Competitor Analysis: Emerging Diabetes Drugs

Publisher: La Merie Publishing
Pages: 104
Format: PDF
Product Line:
Competitor Analysis
Version: Download file
Product Code: LMCA0030
Release Date: April of 2011

600.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Emerging Diabetes Drugs & Targets

Product description

The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.


  • Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors
  • 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
  • Glucokinase Activators (GKA)
  • Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
  • Sirtuin (SIRT) Activators
  • Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
  • Glucagon Receptor (GCGR) Antagonists
  • Glucocorticoid Receptor (GCGR) Antagonists
  • Novel Insulin Sensitizers
  • G-Protein Coupled Receptor 119 (GPR119) Agonists
  • Other Drugs Augmenting GLP-1 Secretion: GPR40, GR120 & TGR5 Agonists
  • Other Glucometabolic Approaches
  • Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
  • Other Metabolic Approaches
  • FGF-21-Receptor Agonists
  • Anti-Inflammatory Approaches
  • Induction of Immune Tolerance
  • Pancreatic Beta Cell Protection & Regeneration
  • Pancreatic Islet Cell Transplantation
  • Various Antidiabetic Approaches

Corporate Emerging Diabetes Drugs R&D Pipelines

  • 7TM Pharma
  • Abbott
  • AdiStem
  • Advinus Therapeutics
  • Alize Pharma
  • Ambrx
  • Amgen
  • Amylin Pharmaceuticals
  • Andromeda
  • Arena Pharmaceuticals
  • Array BioPharma
  • Astellas Pharma
  • AstraZeneca
  • Bayhill Therapeutics
  • Betagenon
  • BHV Pharma
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Catabasis Pharmaceuticals
  • Cellonis Biotechnologies
  • ChemoCentryx
  • Columbia University Medical Center
  • Connexios Life Sciences
  • Cortendo
  • CureDM Group
  • Cyclacel
  • Cytos Biotechnology
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Debiopharm
  • DiaKine Therapeutics
  • Diamedica
  • Diamyd Medical
  • Eli Lilly
  • Ensemble Discovery
  • Evotec
  • Exsulin
  • Forest Laboratories
  • Genzyme
  • Geron Corp
  • GlaxoSmithKline (GSK)
  • Helsinn
  • High Point Pharmaceuticals
  • Immunocore
  • Incyte
  • Inovio
  • Intercept Pharmaceuticals
  • Ipsen
  • ISIS Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson (J&J)
  • Kalypsys
  • Karo Bio
  • Kotobuki
  • Les Laboratoires Servier (Servier)
  • Lexicon Pharmaceuticals
  • LG Life Science
  • Ligand Pharmaceuticals
  • Living Cell Technologies (LCT)
  • MacroGenics
  • MedImmune
  • Melior Discovery
  • Mesoblast
  • Metabolex
  • Merck & Co.
  • Mercury Therapeutics
  • MicroIslet
  • Mitsubishi Tanabe Pharma
  • Neurocrine Biosciences
  • National Institutes of Health (NIH)
  • Novartis
  • NovImmune
  • Omni Bio Pharmaceutical
  • Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)
  • Ortho McNeil (J&J)
  • Osiris therapeutics
  • Pfizer
  • PharmaFrontier
  • Pinnacle
  • Piramal Life Sciences
  • Poxel
  • Rigel Pharmaceuticals
  • Roche
  • Sanofi-Aventis
  • S2 Therapeutics
  • Santarus
  • Sanwa Kagaku Kenkyusho
  • Sirona Biochem
  • Takeda Pharmaceutical
  • Targacept
  • Teva Pharmacetical Industries
  • Theracos
  • Tolera Therapeutics
  • Tolerx
  • TransTech Pharma
  • VeroScience
  • Versartis
  • VIA Pharmaceuticals
  • ViaCyte
  • Vitae Pharmaceuticals
  • Wellstat Therapeutics
  • XOMA
  • Yuhan Co.
  • Zydus Cadila

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up